WO2011064254A1 - Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 - Google Patents

Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 Download PDF

Info

Publication number
WO2011064254A1
WO2011064254A1 PCT/EP2010/068126 EP2010068126W WO2011064254A1 WO 2011064254 A1 WO2011064254 A1 WO 2011064254A1 EP 2010068126 W EP2010068126 W EP 2010068126W WO 2011064254 A1 WO2011064254 A1 WO 2011064254A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
herpes
hsv3
characterized
use according
Prior art date
Application number
PCT/EP2010/068126
Other languages
English (en)
French (fr)
Inventor
Jacqueline Le Goaster
Original Assignee
Jacqueline Le Goaster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0958313A priority Critical patent/FR2952825B1/fr
Priority to FR0958313 priority
Application filed by Jacqueline Le Goaster filed Critical Jacqueline Le Goaster
Publication of WO2011064254A1 publication Critical patent/WO2011064254A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25Varicella-zoster virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PCT/EP2010/068126 2009-11-24 2010-11-24 Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 WO2011064254A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0958313A FR2952825B1 (fr) 2009-11-24 2009-11-24 Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
FR0958313 2009-11-24

Publications (1)

Publication Number Publication Date
WO2011064254A1 true WO2011064254A1 (fr) 2011-06-03

Family

ID=42102368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068126 WO2011064254A1 (fr) 2009-11-24 2010-11-24 Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2

Country Status (2)

Country Link
FR (1) FR2952825B1 (en))
WO (1) WO2011064254A1 (en))

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2092100A1 (en)) 1970-04-28 1972-01-21 Merck & Co Inc
EP0251534B1 (en) 1986-06-20 1993-08-25 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
EP0573107B1 (en) 1992-06-04 2001-10-04 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
WO2006094756A2 (en) 2005-03-03 2006-09-14 Glaxosmithkline Biologicals S.A. Varicella zoster virus vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2092100A1 (en)) 1970-04-28 1972-01-21 Merck & Co Inc
EP0251534B1 (en) 1986-06-20 1993-08-25 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
EP0573107B1 (en) 1992-06-04 2001-10-04 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
EP1097988B1 (en) 1992-06-04 2008-12-31 Merck & Co., Inc. Process for culturing cells in a monolayer
WO2006094756A2 (en) 2005-03-03 2006-09-14 Glaxosmithkline Biologicals S.A. Varicella zoster virus vaccine

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COREY J INFECT DIS vol. 195, 2007, pages 1242 - 1244
FERENCZY MICHAEL W: "Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.", CURRENT PHARMACEUTICAL DESIGN 2007 LNKD- PUBMED:17627531, vol. 13, no. 19, 2007, pages 1975-1988, XP002578572, ISSN: 1873-4286 *
HEINEMAN T C ET AL: "Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.", JOURNAL OF VIROLOGY DEC 1995 LNKD- PUBMED:7494331, vol. 69, no. 12, décembre 1995 (1995-12), pages 8109-8113, XP002578571, ISSN: 0022-538X *
HEINEMAN THOMAS C ET AL: "Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge.", VACCINE 30 JUN 2004 LNKD- PUBMED:15193381, vol. 22, no. 20, 30 juin 2004 (2004-06-30) , pages 2558-2565, XP002578570, ISSN: 0264-410X *
KITAMURA K ET AL: "Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB", VIROLOGY, ACADEMIC PRESS,ORLANDO, US LNKD- DOI:10.1016/0042-6822(86)90088-7, vol. 149, no. 1, 1 février 1986 (1986-02-01), pages 74-82, XP023048692, ISSN: 0042-6822 [extrait le 1986-02-01] *
KUEHN J E ET AL: "HSV-1 GB AND VZV GP-II CROSSREACTIVE ANTIBODIES IN HUMAN SERA", ARCHIVES OF VIROLOGY, SPRINGER WIEN, AT LNKD- DOI:10.1007/BF01323165, vol. 112, 1 janvier 1990 (1990-01-01), pages 203-213, XP000917152, ISSN: 0304-8608 *
LORETTE ET AL. J. AM ACAD DERMATOL vol. 55, 2006, pages 225 - 232
MCGEOCH ET AL. J VIROL vol. 74, 2000, pages 10401 - 10406
STANBERRY ET AL. CLIN.INFECT DIS vol. 30, 2000, pages 549 - 66
STANBERRY ET AL. N ENGL JMED vol. 347, 2002, pages 1652 - 61
STANBERRY ET AL. NENGL JMED vol. 347, 2002, pages 1652 - 61

Also Published As

Publication number Publication date
FR2952825B1 (fr) 2012-05-25
FR2952825A1 (fr) 2011-05-27

Similar Documents

Publication Publication Date Title
Webster Immunity to influenza in the elderly
Chanock et al. Influence of Immunological Factors in Respiratory Syncytial Virus Disease: Of the Lower Respiratory Tract
Manickan et al. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Scolnick et al. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA
Van de Perre et al. Herpes simplex virus and HIV-1: deciphering viral synergy
Asano et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine
Koelle et al. Recent progress in herpes simplex virus immunobiology and vaccine research
Johnston et al. HSV-2: in pursuit of a vaccine
Odumade et al. Progress and problems in understanding and managing primary Epstein-Barr virus infections
Hayden et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
Stanberry et al. Prospects for control of herpes simplex virus disease through immunization
Lubinski et al. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo
JP3530526B2 (ja) HSV糖蛋白質gDおよび3脱アシル化モノホスホリルリピッドAからなる単純ヘルペスワクチン
Talaat et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults
Braaten et al. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine
Straus et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
Bernstein et al. Herpes simplex virus vaccines
Kaarthigeyan Cervical cancer in India and HPV vaccination
Mueller et al. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency
JP4694745B2 (ja) 新規組成物
Bernstein et al. Immune response to influenza vaccination in a large healthy elderly population
Erlich et al. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS): an uncontrolled trial
JP4510283B2 (ja) 併合ワクチン組成物
Kleymann Agents and strategies in development for improved management of herpes simplex virus infection and disease
CZ2002843A3 (cs) Vakcinační prostředek

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790364

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 10790364

Country of ref document: EP

Kind code of ref document: A1